Global Heart Failure Academy

Global Heart Failure Academy

By ReachMDMedicine
Download on the App Store

Global Heart Failure Academy episodes

  • Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
    Guest: Faiez Zannad, MD, PhD
    Guest: John McMurray, MD

    Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.

    17 min
  • Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
    Guest: David Wheeler, MB, CHB, MD, FRCP

    Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.

    16 min
  • AFFIRM-AHF: Key Takeaways
    Host: Ewa A. Jankowska, MD, PhD, FESC

    Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?

    6 min
  • Late-breaking First Response on AFFIRM-AHF
    Host: Stefan D. Anker, MD, PhD
    Guest: Javed Butler, MD
    Guest: Ewa A. Jankowska, MD, PhD, FESC
    Guest: Josep Comin-Colet, MD, PhD

    How does treatment of iron deficiency affect outcomes in patients hospitalized for acute decompensated heart failure? This late-breaking video brief reviews the topline results of the AFFIRM-AHF data released at the 2020 American Heart Association Scientific Sessions and provides reactions from several heart failure experts on what these data mean on a global level.

    8 min
  • CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline-directed RAASi Therapy
    Host: Mikhail Kosiborod, MD

    Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.

    6 min

About Global Heart Failure Academy

From the publisher's feed

Leading global experts have combined guideline recommendations and new clinical data with practical, case-based formats that approximate clinical reality to improve patient outcomes in the management of heart failure.  This series is focused on changing clinical behavior in the recognition and diagnoses of hyperkalemia and iron deficiency in heart failure, through the application of emerging science into everyday practice.